Related Experiment Video
Updated: Feb 17, 2026
08:25
Heterotopic Mucosal Engrafting Procedure for Direct Drug Delivery to the Brain in Mice
Published on: July 16, 2014
11.3K
Bypassing the blood-brian barrier using established skull base reconstruction techniques.
Marcel M Miyake1,2,3, Benjamin S Bleier1
1Department of Otology and Laryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
World Journal of Otorhinolaryngology - Head and Neck Surgery
|December 6, 2017
Summary
A novel transnasal technique permanently bypasses the blood-brain barrier (BBB) using autologous tissues. This breakthrough enables direct central nervous system (CNS) drug delivery for neurological disorders, overcoming previous limitations.
Area of Science:
- Neurosurgery
- Drug Delivery Systems
- Regenerative Medicine
Background:
- Neurological disorders pose a significant global health challenge, with limited treatment options due to the blood-brain barrier (BBB).
- The BBB restricts over 98% of potential neuropharmaceuticals from entering the central nervous system (CNS).
- Current methods to overcome the BBB are invasive, costly, and not scalable for chronic patient needs.
Purpose of the Study:
- To develop and evaluate an innovative method for direct drug delivery across the BBB.
- To establish a safe, chronic, and scalable pathway for neuropharmaceuticals into the CNS.
Main Methods:
- Utilized established endoscopic skull base nasoseptal flap reconstruction techniques.
- Developed a novel method for direct central nervous system (CNS) drug delivery using heterotopic mucosal grafts.
- Demonstrated CNS delivery of large molecules exceeding typical BBB permeability.
Main Results:
- Successfully demonstrated CNS delivery of chromophore-tagged molecules 1000 times larger than typically permitted by the BBB.
- The technique utilizes purely autologous tissues, creating a permanent bypass.
- Achieved direct CNS drug delivery, overcoming the limitations of the blood-brain barrier.
Conclusions:
- This novel technique represents the first described method of permanently bypassing the blood-brain barrier using autologous tissues.
- Offers a potential paradigm shift in treating neurological diseases by enabling targeted delivery of high molecular weight neuropharmaceuticals.
- Provides a safe and chronic transnasal delivery pathway for advanced neurological therapies.
